Regular Article
Quantification of BK1-5, the Stable Bradykinin Plasma Metabolite in Humans, by a Highly Accurate Liquid-Chromatographic Tandem Mass Spectrometric Assay

https://doi.org/10.1006/abio.2001.5073Get rights and content

Abstract

Bradykinin is a vasoactive nonapeptide involved in cardiorenal physiology and inflammatory states. It has been linked to the pathophysiology of hypertension and diabetes. Correlating levels of bradykinin with disease states has been hampered by its rapid degradation, artifactual production during blood sampling, and nonspecific radioimmunoassay techniques. We previously identified BK1-5 as the stable in vivo plasma metabolite of systemic bradykinin in humans. We now report a sensitive and specific assay method for BK1-5 in human blood utilizingliquid chromatography–tandem mass spectrometry(MS) with electrospray ionization. [13C2,15N]Glycine was incorporated into chemically synthesized BK1-5 for use as an internal standard. Blood samples (5 ml) were collected into 15-ml chilled ethanol to prevent artifactual kinin production and degradation. BK1-5 in ethanolic plasma supernatant was purified on a polymeric solid phase extraction cartridge. MS analysis was in the selective reaction monitoring mode. Precision of the assay is ±7.5% and accuracy is 99%. Recovery of BK1-5 through sample preparation was 43% and the lower limit of detection is 4 fmol/ml blood. Concentrations of BK1-5 in 12 normal volunteers were 44.2 ± 7.1 fmol/ml blood (mean ± SE). During blood sampling, no artifactual production of BK1-5 was detected for up to 60 s prior to denaturing the sample. This assay provides the first accurate and precise method using MS to quantify BK1-5 in human blood as a marker for the production of systemic bradykinin in humans.

References (16)

  • L.J. Roberts et al.

    J. Biol. Chem.

    (1996)
  • W. Linz et al.

    Pharmacol. Rev.

    (1995)
  • K.D. Bhoola et al.

    Pharmacol. Rev.

    (1992)
  • P.M. Vanhoutte

    Hypertension

    (1989)
  • N.J. Brown et al.

    Hypertension

    (1999)
  • A.A.K. Hasan et al.

    Circulation

    (1996)
  • M.M. Prechel et al.

    J. Pharmacol. Exp. Ther.

    (1995)
There are more references available in the full text version of this article.

Cited by (36)

  • Tutorial review for peptide assays: An ounce of pre-analytics is worth a pound of cure

    2023, Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences
  • Laboratory Approaches for Assessing Contact System Activation

    2017, Immunology and Allergy Clinics of North America
  • Bradykinin analysis revived - A validated method for determination of its stable metabolite in whole blood by LC-MS/MS

    2014, Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences
    Citation Excerpt :

    The efficient clearance of BK results in a half-life calculated to be less than 0.5 min [17]. An alternative to the direct assay of BK was presented by Murphey et al. who made use of a more stable metabolite of BK, the pentapeptide BK1–5, as a marker for the amount of BK released in vivo [18,19]. This method, however, proved difficult to reproduce, and lacks important validation data according to established validation guidelines [20,21].

  • Quantitative assay for bradykinin in rat plasma by liquid chromatography coupled to tandem mass spectrometry

    2011, Journal of Pharmaceutical and Biomedical Analysis
    Citation Excerpt :

    Reported BK serum or plasma concentrations measured by immunoassays vary largely between the nanomolar and the picomolar range [13]. Other assays, using LC–MS, have been applied to quantify bradykinin in rat muscle tissue dialysate [14], or bradykinin's stable metabolite, BK 1-5, in human blood [15]. Van den Broek et al. in a recent work describing a LC–MS/MS method for the quantification of bradykinin and other peptides in human patients reports plasma concentrations in the order of ng/mL [16].

View all citing articles on Scopus
View full text